עלון מידע
PARKILYNE (Tablets)
SCHEDULING STATUS:
S4
PROPRIETARY NAME
(and dosage form):
PARKILYNE (Tablets)
COMPOSITION:
Each tablet contains 5 mg
selegiline
hydrochloride: ((R)-(-)-N, alpha-dimethyl-N-2-propynyl-phenethylamine
hydrochloride).
PHARMACOLOGICAL CLASSIFICATION:
A 5.4.1. Anti-Parkinsonism preparations.
PHARMACOLOGICAL ACTION:
Selegiline is a selective MAO-B (monoamine oxidase type B) inhibitor which prevents the breakdown of dopamine in the
brain. It also inhibits the re-uptake of dopamine at pre-synaptic dopamine receptors. These effects potentiate
dopaminergic function in the brain. Thus selegiline acts in Parkinsonism by potentiating and prolonging the effect of
levodopa.
Pharmacokinetics:
Selegiline is rapidly absorbed from the gastro-intestinal tract.
It crosses the blood-brain barrier.
It is rapidly and completely metabolized to N-desmethyldeprenyl, L-methamphetamine and L-amphetamine. The mean
half-lives of the 3 active metabolites that were found in serum and urine following a single dose of selegiline are as
follows:
N-desmethyldeprenyl 2 hours
L-methamphetamine 17.7 hours
L-amphetamine 20.5 hours
Selegiline is 94% bound to plasma proteins at therapeutic concentrations.
INDICATIONS:
PARKILYNE is indicated in the management of early morning akinesia and nocturnal akinesia in patients with
Parkinson’s disease being treated with levodopa alone or levodopa and a peripheral decarboxylase inhibitor. At the end-
stage of Parkinson’s disease, response may be markedly reduced.
CONTRA-INDICATIONS:
PARKILYNE is contra-indicated in patients with a known hypersensitivity to any of the ingredients.
PARKILYNE should be avoided in patients with active ulceration.
PARKILYNE is contra-indicated in patients receiving serotonin receptor agonists such as sumatriptan
קרא את המסמך השלם